Effecta Pharma

Name

Effecta Pharma

Legal name

Effecta Pharma Pvt Ltd

Website

https://effectapharma.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Effecta Pharma is a UK-based, privately held pharmaceutical R&D company focused on discovering and developing innovative medicines for viral diseases. It operates with 1-10 employees under founder Helmuth van Es and has no disclosed pipeline, funding, or commercial activity.

Ownership category

akta.pro rank

Product category

Antiviral Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Antiviral drug discovery
• Viral disease therapeutics
• Pharmaceutical R&D
• Innovative medicines
• Biopharmaceutical development

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Core offering

Effecta Pharma Limited is a UK-based pharmaceutical company dedicated to the discovery and development of innovative medicines to treat viral diseases. The company focuses on antiviral drug discovery as its core activity, operating as a small (1-10 employee) private entity.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• Gilead Sciences: Large biopharmaceutical company with a dominant antiviral franchise (HIV, HCV, HBV, influenza, COVID-19 via remdesivir). Comparable as the dominant antiviral incumbent setting the standard for drug development in the same therapeutic indications.
• Pfizer: Global pharmaceutical company with a major antiviral portfolio including Paxlovid (COVID-19) and extensive historical antiviral R&D investment. Comparable as a broad incumbent with deep resources in viral disease therapeutics.
• Shionogi: Japanese pharmaceutical company with a strong antiviral portfolio including Xocova (COVID-19) and baloxavir (influenza). Comparable as a broad incumbent with material antiviral R&D investments and global commercialization.
• Merck & Co. Global pharmaceutical company with significant antiviral assets including molnupiravir (COVID-19) and a long-standing HIV franchise. Comparable as a large incumbent with antiviral R&D scale and regulatory expertise.

Direct peers

• Ridgeback Biotherapeutics: Privately-held biotech focused on antiviral and anti-infective therapies, including oral antivirals for Ebola and COVID-19. Comparable as a small privately-held antiviral specialty company with a similar operating model.
• Vir Biotechnology: Clinical-stage immunology company with a major focus on serious infectious diseases including viral targets (hepatitis B, influenza, HIV). Comparable as a small, publicly-traded specialist developing innovative antiviral therapeutics, with a similar therapeutic mandate to Effecta Pharma.
• Atea Pharmaceuticals: Clinical-stage biopharmaceutical company focused on discovery, development, and commercialization of antiviral therapeutics. Directly comparable to Effecta Pharma in therapeutic area (oral direct-acting antivirals) and lean, focused R&D model.
• Pardes Biosciences: Preclinical-to-clinical stage company developing oral antiviral therapies, with a focus on SARS-CoV-2 and other viral targets. Comparable as a small, focused antiviral discovery and development specialist.
• Arbutus Biopharma: Clinical-stage biopharmaceutical company developing a cure for chronic hepatitis B and other viral infections. Directly comparable therapeutic focus area (chronic viral disease) with a small, focused antiviral pipeline.
• Cocrystal Pharma: Clinical-stage biotechnology company developing novel antiviral therapeutics for influenza, coronavirus, hepatitis B, and norovirus. Comparable as a small antiviral-focused discovery company operating in similar viral disease indications.

Market position

Customer concentration

• LinkedInlinkedin.com/company/effecta-pharma-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Effecta Pharma